The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Basit Öğe Kaydı
dc.authoridKorkmaz, Mustafa/0000-0003-0926-6748
dc.authoridKESKİNKILIÇ, MERVE/0000-0002-3342-3144
dc.authoridYildirim, Hasan cagri/0000-0003-3060-377X
dc.authoridMUTLU, EMEL/0000-0002-1008-2527
dc.authoridKayikcioglu, Erkan/0000-0002-7401-5446
dc.authorwosidKorkmaz, Mustafa/AAC-7120-2022
dc.authorwosidKESKİNKILIÇ, MERVE/HNR-2564-2023
dc.authorwosidKutlu, Yasin/JCN-7126-2023
dc.contributor.authorYildirim, Hasan Cagri
dc.contributor.authorKutlu, Yasin
dc.contributor.authorMutlu, Emel
dc.contributor.authorAykan, Musa Baris
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorYalcin, Selim
dc.contributor.authorSakalar, Teoman
dc.date.accessioned2024-05-19T14:43:09Z
dc.date.available2024-05-19T14:43:09Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractIntroductionMale breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 -) breast cancer in women, limited data exist on their effectiveness in male patients.We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer.IntroductionMale breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 -) breast cancer in women, limited data exist on their effectiveness in male patients.We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer.MethodsThis study is a multicenter, retrospective study. We included male patients with HR + and HER2-metastatic breast cancer who received palbociclib or ribociclib as first-line treatment. Our primary endpoints were progression-free survival (PFS), overall response rates (ORR), and drug-related adverse effects.ResultsA total of 46 male patients from 27 institutions were enrolled. The median age at initiation of CDK 4/6 inhibitors was 63.64 +/- 13.69 years, with a median follow-up of 21.33 (95% CI 14.92-27.74) months. The ORR were 84% for palbociclib and 76.2% for ribociclib. The mPFS for the entire cohort was 28.06 months (95% CI 18.70-37.42). No significant difference in PFS was observed between palbociclib and ribociclib (mPFS: 24.46 months (95% CI 11.51-37.42) vs 28.33 months (95% CI 14.77-41.88), respectively, p = 0.211). No new adverse events were reported.DiscussionThis study demonstrates that palbociclib and ribociclib are effective and safe options for first-line treatment in male patients with HR + /HER2 - metastatic breast cancer. However, further prospective studies are warranted to establish their efficacy in this population.en_US
dc.identifier.doi10.1007/s10147-023-02460-5
dc.identifier.endpage265en_US
dc.identifier.issn1341-9625
dc.identifier.issn1437-7772
dc.identifier.issue3en_US
dc.identifier.pmid38310597en_US
dc.identifier.scopus2-s2.0-85184191440en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage258en_US
dc.identifier.urihttps://doi.org10.1007/s10147-023-02460-5
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5326
dc.identifier.volume29en_US
dc.identifier.wosWOS:001156854500001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Japan Kken_US
dc.relation.ispartofInternational Journal of Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectMale Breast Canceren_US
dc.subjectCdk4/6 Inhibitorsen_US
dc.subjectPalbocicliben_US
dc.subjectRibocicliben_US
dc.titleThe efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu